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Every thoracic surgeon should know about Archie Cochrane. He is asclose to a true hero as a physician can get, but I am sure there arethose who see him as the devil incarnate. As is apparent from someof the highlights of his career (Table 1), he lived during an excitingtime. In the 1930s Professor Cochrane was branded as a “Trotskyite”because he advocated a national health system for Great Britain. His
advocacy was tempered by 4 years being held in multiple German prisoner of war
camps. He saw soldiers die of tuberculosis and he was never sure what the best
treatment was. Believe it or not, he did have some alternate therapies to offer the
soldiers in the prisoner of war camps. He could choose between collapse therapy,
bed rest, supplemental nutrition, or even high-dose vitamin therapy. A quote from
his book1 sums up his frustration: “I had considerable freedom of clinical choice of
therapy: my trouble was that I did not know which to use and when. I would gladly
have sacrificed my freedom for a little knowledge.”
After the war he continued to lobby for a national health service, and the National
Health Service was created in the early 1950s. His experience with the uncertainty
about the best treatment for tuberculosis and other chest diseases continued after the
war, when he became a researcher in pulmonary disease for the Medical Research
Council in Great Britain. In the late 1940s and early 1950s, drug therapy for
tuberculosis was introduced and there were even some randomized clinical trials
that addressed the issue of the best therapy for tuberculosis. With some encourage-
ment from his friends, Archie embarked on a career that would now be called
medical epidemiology and health planning. Still with an interest in tuberculosis,
now heightened by the fact that he had contracted the disease, Archie wanted to
know the best drug therapy for tuberculosis. There were now drugs available that
could treat this disease, streptomycin being the first really effective drug against
Mycobacterium tuberculosis.2 He was a patron of randomized controlled trials (or
RCTs, as he liked to refer to them) to test important medical hypotheses. He used
the evidence gained from these RCTs to make decisions about the best therapy on
the basis of available evidence—the beginning of “evidence-based” practice. He
believed that RCTs are the best form of evidence to support medical decision
making (so-called “class 1” evidence). Initially he was a voice in the wilderness, but
this changed little by little. In 1979 he criticized the medical profession for not
having a critical summary, organized by specialty and updated periodically, of
relevant RCTs. In the 1980s, a perinatal database of important RCTs was developed
at Oxford. In 1987, the year before Cochrane died, he referred to a systematic review
of RCTs of care during pregnancy and childbirth as “a real milestone in the history
of randomized trials and in the evaluation of care,” and he suggested that other
specialties should copy the methods used. This led to the opening of the first
Cochrane center (in Oxford, United Kingdom) in 1992 and the founding of The
Cochrane Collaboration in 1993. Now the Cochrane Collaboration is a repository of
RCTs, both disease-specific and specialty-specific. Clinicians and lay persons can
go to the Cochrane Web site (http://www.cochrane.org/) and find summaries of all
available RCTs on a wide range of medical subjects. From the above discussion, I
think it is fair to call Archie Cochrane the “father of evidence-based medicine.”
Only one of the thousands of summaries of RCTs found on the Cochrane Collabo-
ration Web site has anything to do with any element of cardiopulmonary bypass (CPB).
The Cochrane Heart Group reviewed the evidence that hypothermia reduces stroke after
coronary artery bypass grafting performed with CPB. In this issue of the Journal, Bartels
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and coworkers3 confirm what the Cochrane reviewers have
known for a long time—there are few if any RCTs that provide
evidence for the way medicine is practiced with regard to CPB.
In summarizing available medical evidence on a given
subject, information retrieval is king. The Cochrane review-
ers were able to find 17 RCTs of adequate quality that
evaluated postoperative stroke in patients having hypother-
mic CPB compared with normothermic CPB. Bartels and
coworkers3 found 11 or fewer! It is important to understand
how the Cochrane reviewers found these 17 RCTs. One has
to realize that only about one third of the world’s medical
literature appears on large computer databases such as
MEDLINE, so simply searching MEDLINE for the RCTs
of interest is not sufficient. Computerized databases such
as MEDLINE are incomplete, especially in areas of sub-
specialization like cardiothoracic surgery. The Cochrane
reviewers perform an exhaustive search of all available
literature, not only MEDLINE, but unpublished trials and
so-called “fugitive literature” (eg, government reports, pro-
ceedings of conferences, published PhD theses). The aver-
age thoracic surgeon has not heard of “publication bias,” but
the Cochrane reviewers have. They realize that RCTs that have
a negative result are less likely to pass the peer-review editorial
process into publication than RCTs with a significant treatment
effect: so-called publication bias in favor of positive clinical
trials. For each of the Cochrane reviews, attempts are made to
find unpublished, negative trials to add to the body of evidence
about a given subject. By these standards, the search for RCTs
in the article by Bartels and coworkers3 is incomplete.
If information retrieval is king in summarizing available
medical evidence on a given subject, then statistical analysis
of the retrieved studies (including RCTs) must surely share
the throne. It must be obvious that all trials or observational
studies that address the same outcomes of a given interven-
tion are not the same. There are almost always subtle
differences in study design, sample size, analysis of results,
and inclusion/exclusion criteria. The object of comparing
multiple observational studies and RCTs on the same treat-
ment outcome is to come up with a single summary estimate
of the effect of the intervention. Calculating a single esti-
mate in the face of such diversity may give a misleading
picture of the truth. There are no statistical tricks that
account for bias and confounding in the original studies.
Heterogeneity of the various RCTs and observational stud-
ies on the same or similar treatment outcomes are the issues.
This heterogeneity makes comparison of RCTs a daunting
task, about which volumes have been written.4
There are at least two types of heterogeneity that con-
found summary estimates of multiple RCTs: clinical heter-
ogeneity and statistical heterogeneity. Statistical heteroge-
neity is present when the between-study variance is large,
that is, similar treatments result in widely varying outcomes
in different trials. This form of heterogeneity is easiest to
measure. For example, Berlin and coworkers5 evaluated 22
separate meta-analyses and found that only 14 of 22 had no
evidence of statistical heterogeneity. Three of the remaining
8 comparative studies gave different results depending on
the type of statistical methods used for the analysis: the
more statistical heterogeneity, the less certain the statistical
inferences from the analysis.
Clinical heterogeneity of groups of RCTs that assess
similar outcomes is much more difficult to assess. Measure-
ment of treatment outcomes has plagued reviewers who try
to summarize RCTs. Many RCTs address similar treatment
options (eg, hypothermic CPB vs normothermic CPB) but
measure slightly different outcomes (eg, stroke or neuro-
psychologic dysfunction). For example, the Cochrane Heart
Group found 17 RCTs that addressed the effect of CPB
temperature on stroke. Only 4 of these 17 RCTs measured
neuropsychologic function whereas all 17 measured neuro-
logic deficit associated with CPB. In summarizing the re-
sults of multiple RCTs comparing a given treatment, it is
necessary to match “apples with apples” when looking at
outcomes. It is disturbing that Bartels and coworkers list
multiple outcome measures for most CPB interventions. As
an example, for the optimal core temperature for CPB, they
list 8 outcomes covering the entire spectrum from death to
myocardial infarction to stroke to postoperative blood trans-
fusion. In a similar analysis by the Cochrane Heart Group,
there was a trend toward a reduction in the incidence of
nonfatal strokes in the hypothermic group (odds ratio 0.68
[0.43, 1.05]). Conversely, there was a trend for the number
of non-stroke–related perioperative deaths to be higher in
the hypothermic group (odds ratio 1.46 [0.9, 2.37]). When
all “bad” outcomes (stroke, perioperative death, myocardial
TABLE 1. Archie Cochrane
● 1934-1936: Medical student, University College Hospital,
London
● 1936: International Brigade, Spanish Civil War
● 1939-1946: Captain, Royal Army Medical Corps
● 1941: Taken prisoner of war in June 1941 in Crete; prisoner
of war medical officer in Salonica (Greece) and
Hildburghausen, Elsterhorst and Wittenberg-am-Elbe
(Germany)
● 1947-1948: Studied the epidemiology of tuberculosis at Henry
Phipps Institute, Philadelphia, Pennsylvania
● 1948-1960: Member, Medical Research Council
Pneumoconiosis Research Unit, Penarth, Wales
● 1960-1969: David Davies Professor of Tuberculosis and Chest
Diseases, Welsh National School of Medicine, Cardiff,
Wales
● 1960-1974: Director, Medical Research Council Epidemiology
Research Unit, Cardiff, Wales
● 1972: Publication by the Nuffield Provincial Hospitals Trust
of his book Effectiveness and Efficiency—Random
Reflections on Health Services
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infarction, low output syndrome, intra-aortic balloon pump
use) were pooled, there was no significant advantage of
either hypothermia or normothermia (odds ratio 1.07 [0.92,
1.24]). This suggests clinical heterogeneity among the var-
ious RCTs evaluated. There are statistical “tricks” that can
investigate and explore the differences among studies, such
things as stratification or regression, but none of these
evaluations of clinical heterogeneity was used in the study
by Bartels and coworkers.3
Of interest, the Cochrane Heart Group concludes that there
is no definite advantage of hypothermia over normothermia in
the incidence of clinical events after CPB. This constitutes
A-level evidence (multiple well-done RCTs) to support the
notion that normothermic and hypothermic CPB have equal
efficacy for most outcomes. An expert panel reviewing the
Cochrane evidence might suggest that there is good evidence
(ie, class I evidence according to the American College of
Cardiology/American Heart Association [ACC/AHA] guide-
line nomenclature) that neither normothermic nor hypothermic
CPB results in an increased incidence of perioperative com-
plications. This is an entirely different conclusion from the
conclusion that Bartels and coauthors reach about the same
intervention, because they suggest that there is little evidence
to support the usefulness/efficacy of hypothermia in CPB (their
so-called level III). For this reason, I am skeptical of the
authors’ classification of the level of evidence of the various
CPB principles. They state that different randomized trials
gave conflicting results for a given principle of CPB and,
therefore, that principle was automatically given a scientific
level II or level III classification. This is neither the intent nor
the letter of the various guidelines published for determining
evidence-based interventions.6 For example, for an interven-
tion such as roller pump versus centrifugal pump to be con-
sidered class II by the ACC/AHA guidelines, there would have
to be conflicting evidence or divergence of opinion about the
usefulness of, or the efficacy of, either intervention. There is
neither conflicting evidence nor divergence about the useful-
ness of either intervention. Both work and there is very little
difference between the two. A more reasonable interpretation
of the available evidence from randomized trials might be that
both interventions (roller pump and centrifugal pump) are
equally efficacious. There is almost no information in the
Bartels manuscript to back up their contention about classifi-
cation of the various CPB principles. Without better documen-
tation of the classification of each of the levels of evidence, the
reader gets the impression that the authors have an ax to grind
or have some bias about CPB interventions.
In truth, I think Archie Cochrane would turn over in his
grave if he knew how we worship at the alter of RCTs.
Archie realized early on that some things cannot and should
not be subjected to RCTs, something that Bartels and co-
workers have not acknowledged. Archie thought that an
RCT that addressed the efficacy of penicillin was unethical,
because half of the study group would be denied the stan-
dard treatment. Cochrane cited examples of interventions
that would never be subjected to RCTs because of ethical
concerns. They include cytologic tests for prevention of
cervical carcinoma, pulmonary resection for lung cancer,
and diet therapy for phenylketonuria. If he could read the
articles by Bartels and associates, I suspect he would in-
clude many of their principles of CPB in this category. Is it
ethical to deny a high-risk patient the benefit of retrograde
cardioplegia to prove efficacy of this type of myocardial
protection? Most surgeons would say that an RCT is un-
necessary and possibly unethical in this situation.
The Editor and the reviewers struggled long and hard
with the manuscript by Bartels and colleagues. I suspect
that, in the end, the decision to publish the manuscript was
based as much on a desire to emphasize the need for a
strong evidence-base to support what we do as thoracic
surgeons, as on the scientific merit of the publication. The
simple fact is that there are gaps in the scientific content of
the manuscript by Bartels and associates. However, these
gaps are understandable, possibly unimportant, and do not
detract from the important principle that evidence-based
medicine is here to stay. If he were living, Archie Cochrane
would enjoy reading the Bartels manuscript, if for no other
reason than the manuscript suggests that we have come full
circle. The need for evidence-based medicine had its roots
in the chest disease of tuberculosis and now, more than 50
years later, these principles have finally returned to the chest
in the form of the heart-lung machine.
References
1. Cochrane A. Effectiveness and efficiency—random reflections on
health services. London: Royal Society of Medicine Press Limited,
1971.
2. Daniels M, Hill A. Chemotherapy of pulmonary tuberculosis in young
adults: an analysis of the combined results of three Medical Research
Council trials. Br Med J. 1952;1:1162.
3. Bartels C, Gerdes A, Babin-Ebell J, Beyersdorf F, Boeken U, Doenst
T, et al. Cardiopulmonary bypass: Evidence or experience based?
J Thorac Cardiovasc Surg. 2002;124:20-7.
4. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness
analysis: methods for quantitative synthesis in medicine. 2nd ed.
Oxford: Oxford University Press, 2000.
5. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of
statistical methods for combining event rates from clinical trials. Stat
Med. 1989;8:141-51.
6. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD,
Hochman JS, et al. ACC/AHA guidelines for the management of
patients with unstable angina and non-ST-segment elevation myocar-
dial infarction: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Com-
mittee on the Management of Patients With Unstable Angina). J Am
Coll Cardiol. 2000;36:970-1062.
Ferraris Editorials
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 1 13
ED
IT
O
RI
A
L
